These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 37294663)

  • 41. Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis.
    Cullinane C; Fleming C; O'Leary DP; Hassan F; Kelly L; O'Sullivan MJ; Corrigan MA; Redmond HP
    JAMA Netw Open; 2020 Nov; 3(11):e2026921. PubMed ID: 33211112
    [TBL] [Abstract][Full Text] [Related]  

  • 42. GOLPH3 overexpression correlates with poor response to neoadjuvant therapy and prognosis in locally advanced rectal cancer.
    Zhu K; Zhao Q; Yue J; Shi P; Yan H; Xu X; Wang R
    Oncotarget; 2016 Oct; 7(42):68328-68338. PubMed ID: 27634904
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
    Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
    [No Abstract]   [Full Text] [Related]  

  • 44. Is adjuvant chemotherapy necessary for patients with pathological complete response after neoadjuvant chemoradiotherapy and radical surgery in locally advanced rectal cancer? Long-term analysis of 40 ypCR patients at a single center.
    Zhou J; Qiu H; Lin G; Xiao Y; Wu B; Wu W; Sun X; Lu J; Zhang G; Xu L; Liu Y
    Int J Colorectal Dis; 2016 Jun; 31(6):1163-8. PubMed ID: 27044403
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A good preoperative immune prognostic index is precits a better prognosis for locally advanced rectal cancer patients with ypTNM stage II who underwent radical resection after neoadjuvant chemoradiotherapy.
    Li S; Wang Y; Cai H; Pan Z; Guan G
    Int J Colorectal Dis; 2023 Jul; 38(1):184. PubMed ID: 37395868
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Clinicopathological and prognostic features of young onset patients with middle-low rectal cancer received neoadjuvant chemoradiotherapy].
    Zhang QQ; Wu YL; Li DD; Shen SH; Fang H; Zhu YL; Zhang HZ
    Zhonghua Zhong Liu Za Zhi; 2021 May; 43(5):574-580. PubMed ID: 34034478
    [No Abstract]   [Full Text] [Related]  

  • 47. Total neoadjuvant therapy versus standard therapy in locally advanced rectal cancer: A systematic review and meta-analysis of 15 trials.
    Zhang X; Ma S; Guo Y; Luo Y; Li L
    PLoS One; 2022; 17(11):e0276599. PubMed ID: 36331947
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The prognostic role of TCF4 expression in locally advanced rectal cancer patients treated with neoadjuvant chemoradiotherapy.
    Dou X; Wang R; Meng X; Yan H; Jiang S; Zhu K; Xu X; Chen D; Song X; Mu D
    Cancer Biomark; 2015; 15(2):181-8. PubMed ID: 25519018
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Systematic review and meta-analysis of long-term oncological outcomes of lateral lymph node dissection for metastatic nodes after neoadjuvant chemoradiotherapy in rectal cancer.
    Kroon HM; Hoogervorst LA; Hanna-Rivero N; Traeger L; Dudi-Venkata NN; Bedrikovetski S; Kusters M; Chang GJ; Thomas ML; Sammour T
    Eur J Surg Oncol; 2022 Jul; 48(7):1475-1482. PubMed ID: 35568607
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pathological complete response may underestimate distant metastasis in locally advanced rectal cancer following neoadjuvant chemoradiotherapy and radical surgery: Incidence, metastatic pattern, and risk factors.
    Sun Y; Wu X; Zhang Y; Lin H; Lu X; Huang Y; Chi P
    Eur J Surg Oncol; 2019 Jul; 45(7):1225-1231. PubMed ID: 30879932
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer: A new era for anal preservation.
    Wang Y; Shen L; Wan J; Zhang H; Wu R; Wang J; Wang Y; Xu Y; Cai S; Zhang Z; Xia F
    Front Immunol; 2022; 13():1067036. PubMed ID: 36569918
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic value of postoperative ctDNA detection in patients with early non-small cell lung cancer: a systematic review and meta-analysis.
    Guo K; Lu J; Lou Y; Zheng S
    Ther Adv Med Oncol; 2023; 15():17588359231177008. PubMed ID: 37256023
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery.
    Weiser MR; Chou JF; Keshinro A; Chapman WC; Bauer PS; Mutch MG; Parikh PJ; Cercek A; Saltz LB; Gollub MJ; Romesser PB; Crane CH; Shia J; Markowitz AJ; Garcia-Aguilar J; Gönen M;
    JAMA Netw Open; 2021 Nov; 4(11):e2133457. PubMed ID: 34748003
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Is neoadjuvant chemoradiotherapy always necessary for mid/high local advanced rectal cancer: A comparative analysis after propensity score matching.
    Zhang Y; Sun Y; Xu Z; Chi P; Lu X
    Eur J Surg Oncol; 2017 Aug; 43(8):1440-1446. PubMed ID: 28502421
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Timing to achieve the best recurrence-free survival after neoadjuvant chemoradiotherapy in locally advanced rectal cancer: experience in a large-volume center in China.
    Wang X; Zheng Z; Zhu H; Yu Q; Huang S; Lu X; Huang Y; Chi P
    Int J Colorectal Dis; 2021 May; 36(5):1007-1016. PubMed ID: 33398511
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Locally advanced rectal cancer transcriptomic-based secretome analysis reveals novel biomarkers useful to identify patients according to neoadjuvant chemoradiotherapy response.
    Canto LMD; Cury SS; Barros-Filho MC; Kupper BEC; Begnami MDFS; Scapulatempo-Neto C; Carvalho RF; Marchi FA; Olsen DA; Madsen JS; Havelund BM; Aguiar S; Rogatto SR
    Sci Rep; 2019 Jun; 9(1):8702. PubMed ID: 31213644
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): a multicenter observational study.
    Borggreve AS; Mook S; Verheij M; Mul VEM; Bergman JJ; Bartels-Rutten A; Ter Beek LC; Beets-Tan RGH; Bennink RJ; van Berge Henegouwen MI; Brosens LAA; Defize IL; van Dieren JM; Dijkstra H; van Hillegersberg R; Hulshof MC; van Laarhoven HWM; Lam MGEH; van Lier ALHMW; Muijs CT; Nagengast WB; Nederveen AJ; Noordzij W; Plukker JTM; van Rossum PSN; Ruurda JP; van Sandick JW; Weusten BLAM; Voncken FEM; Yakar D; Meijer GJ;
    BMC Cancer; 2018 Oct; 18(1):1006. PubMed ID: 30342494
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of a long non-coding RNA signature for prediction of response to neoadjuvant chemoradiotherapy in locally advanced rectal adenocarcinoma.
    Ferrando L; Cirmena G; Garuti A; Scabini S; Grillo F; Mastracci L; Isnaldi E; Marrone C; Gonella R; Murialdo R; Fiocca R; Romairone E; Ballestrero A; Zoppoli G
    PLoS One; 2020; 15(2):e0226595. PubMed ID: 32023246
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Circulating tumor DNA as prognostic markers of relapsed breast cancer: a systematic review and meta-analysis.
    Guo N; Zhou Q; Chen X; Zeng B; Wu S; Zeng H; Sun F
    J Natl Cancer Cent; 2024 Mar; 4(1):63-73. PubMed ID: 39036387
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer.
    Serna G; Ruiz-Pace F; Hernando J; Alonso L; Fasani R; Landolfi S; Comas R; Jimenez J; Elez E; Bullman S; Tabernero J; Capdevila J; Dienstmann R; Nuciforo P
    Ann Oncol; 2020 Oct; 31(10):1366-1375. PubMed ID: 32569727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.